Anna C Davis1,2,3, Ernest Shen4, Nirav R Shah3,5, Beth A Glenn2, Ninez Ponce2, Donatello Telesca6, Michael K Gould7, Jack Needleman2. 1. Kaiser Permanente Center for Effectiveness and Safety Research, Pasadena, CA, USA. 2. Department of Health Policy and Management, University of California Los Angeles Fielding School of Public Health, Los Angeles, CA, USA. 3. Kaiser Permanente Southern California Clinical Operations Support, Pasadena, CA, USA. 4. Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena, CA, USA. 5. Stanford University School of Medicine, Stanford, CA, USA. 6. Department of Biostatistics, University of California Los Angeles Fielding School of Public Health, Los Angeles, CA, USA. 7. Kaiser Permanente Southern California Department of Research and Evaluation, Pasadena, CA, USA. michael.k.gould@kp.org.
Abstract
BACKGROUND: High-cost patients are a frequent focus of improvement projects based on primary care and other settings. Efforts to characterize high-cost, high-need patients are needed to inform care planning, but such efforts often rely on a priori assumptions, masking underlying complexities of a heterogenous population. OBJECTIVE: To define recognizable subgroups of patients among high-cost adults based on clinical conditions, and describe their survival and future spending. DESIGN: Retrospective observational cohort study. PARTICIPANTS: Within a large integrated delivery system with 2.7 million adult members, we selected the top 1% of continuously enrolled adults with respect to total healthcare expenditures during 2010. MAIN MEASURES: We used latent class analysis to identify clusters of alike patients based on 53 hierarchical condition categories. Prognosis as measured by healthcare spending and survival was assessed through 2014 for the resulting classes of patients. RESULTS: Among 21,183 high-cost adults, seven clinically distinctive subgroups of patients emerged. Classes included end-stage renal disease (12% of high-cost population), cardiopulmonary conditions (17%), diabetes with multiple comorbidities (8%), acute illness superimposed on chronic conditions (11%), conditions requiring highly specialized care (14%), neurologic and catastrophic conditions (5%), and patients with few comorbidities (the largest class, 33%). Over 4 years of follow-up, 6566 (31%) patients died, and survival in the classes ranged from 43 to 88%. Spending regressed to the mean in all classes except the ESRD and diabetes with multiple comorbidities groups. CONCLUSIONS: Data-driven characterization of high-cost adults yielded clinically intuitive classes that were associated with survival and reflected markedly different healthcare needs. Relatively few high-cost patients remain persistently high cost over 4 years. Our results suggest that high-cost patients, while not a monolithic group, can be segmented into few subgroups. These subgroups may be the focus of future work to understand appropriateness of care and design interventions accordingly.
BACKGROUND: High-cost patients are a frequent focus of improvement projects based on primary care and other settings. Efforts to characterize high-cost, high-need patients are needed to inform care planning, but such efforts often rely on a priori assumptions, masking underlying complexities of a heterogenous population. OBJECTIVE: To define recognizable subgroups of patients among high-cost adults based on clinical conditions, and describe their survival and future spending. DESIGN: Retrospective observational cohort study. PARTICIPANTS: Within a large integrated delivery system with 2.7 million adult members, we selected the top 1% of continuously enrolled adults with respect to total healthcare expenditures during 2010. MAIN MEASURES: We used latent class analysis to identify clusters of alike patients based on 53 hierarchical condition categories. Prognosis as measured by healthcare spending and survival was assessed through 2014 for the resulting classes of patients. RESULTS: Among 21,183 high-cost adults, seven clinically distinctive subgroups of patients emerged. Classes included end-stage renal disease (12% of high-cost population), cardiopulmonary conditions (17%), diabetes with multiple comorbidities (8%), acute illness superimposed on chronic conditions (11%), conditions requiring highly specialized care (14%), neurologic and catastrophic conditions (5%), and patients with few comorbidities (the largest class, 33%). Over 4 years of follow-up, 6566 (31%) patients died, and survival in the classes ranged from 43 to 88%. Spending regressed to the mean in all classes except the ESRD and diabetes with multiple comorbidities groups. CONCLUSIONS: Data-driven characterization of high-cost adults yielded clinically intuitive classes that were associated with survival and reflected markedly different healthcare needs. Relatively few high-cost patients remain persistently high cost over 4 years. Our results suggest that high-cost patients, while not a monolithic group, can be segmented into few subgroups. These subgroups may be the focus of future work to understand appropriateness of care and design interventions accordingly.
Entities:
Keywords:
comorbidity; health services research; healthcare costs; statistical modeling
Authors: Deborah J Rinehart; Carlos Oronce; Michael J Durfee; Krista W Ranby; Holly A Batal; Rebecca Hanratty; Jody Vogel; Tracy L Johnson Journal: Med Care Date: 2018-01 Impact factor: 2.983
Authors: Jeffrey D Clough; Gerald F Riley; Melissa Cohen; Sheila M Hanley; Darshak Sanghavi; Darren A DeWalt; Rahul Rajkumar; Patrick H Conway Journal: Healthc (Amst) Date: 2015-10-01
Authors: Natalie S Lee; Noah Whitman; Nirav Vakharia; Glen B Taksler; Michael B Rothberg Journal: J Gen Intern Med Date: 2016-08-01 Impact factor: 5.128
Authors: Corinna Koebnick; Annette M Langer-Gould; Michael K Gould; Chun R Chao; Rajan L Iyer; Ning Smith; Wansu Chen; Steven J Jacobsen Journal: Perm J Date: 2012
Authors: Franya Hutchins; Joshua Thorpe; Matthew L Maciejewski; Xinhua Zhao; Karin Daniels; Hongwei Zhang; Donna M Zulman; Stephan Fihn; Sandeep Vijan; Ann-Marie Rosland Journal: J Gen Intern Med Date: 2021-11-03 Impact factor: 6.473
Authors: James Wick; David J T Campbell; Finlay A McAlister; Braden J Manns; Marcello Tonelli; Reed F Beall; Brenda R Hemmelgarn; Andrew Stewart; Paul E Ronksley Journal: CMAJ Open Date: 2022-04-19
Authors: Evelyn T Chang; Jean Yoon; Aryan Esmaeili; Donna M Zulman; Michael K Ong; Susan E Stockdale; Elvira E Jimenez; Karen Chu; David Atkins; Angela Denietolis; Steven M Asch Journal: Health Serv Res Date: 2021-06-18 Impact factor: 3.734
Authors: Shelley-Ann M Girwar; Robert Jabroer; Marta Fiocco; Stephen P Sutch; Mattijs E Numans; Marc A Bruijnzeels Journal: Health Sci Rep Date: 2021-07-23